Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.54 |
| ▸ | SMO | Q99835 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827472 | 0.89 | RAF1 (0.64) | MAPK14NPC1RAB9ATP53MAPK1 | |
| SCHEMBL2967236 | 0.85 | NPC1 (0.50) | MAPK14SMOMAPTSMN1; SMN2NPC1 | |
| SCHEMBL6489471 | 0.84 | TP53 (0.54) | MAPK14MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6486636 | 0.83 | RAB9A (0.55) | MAPK14SMOMAPTSMN1; SMN2NPC1 | |
| SCHEMBL6483554 | 0.83 | TP53 (0.55) | MAPK14MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12764388 | 0.82 | SMN1; SMN2 (0.57) | MAPK14SMOMAPTSMN1; SMN2NPC1 | |
| SCHEMBL12764365 | 0.81 | SMN1; SMN2 (0.58) | MAPK14SMOMAPTSMN1; SMN2NPC1 | |
| SCHEMBL4831633 | 0.78 | BRAF (0.56) | MAPK14MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4257833 | 0.77 | CSF1R (0.66) | MAPK14NPC1RAB9ARAF1BRAF | |
| SCHEMBL6483995 | 0.76 | MAPK14 (0.60) | MAPK14SMOMAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | MAPK14 2054/4885SMO 4147/4885MAPT 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.